▲ 2.14%
prev close
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Congressional Trades
8
All tracked trades
Members Trading
4
Unique members
Net Activity
-2
3 buys · 5 sells
Members Who Traded This Stock
8 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-08-27 | NVSNovartis AG Common Stock | Sell | $15,001 - $50,000 | 25d ago | — | |
| 2025-10-30 | NVSNovartis AG Common Stock | Buy | $1,001 - $15,000 | 333d ago | — | |
| 2025-09-25 | NVSNovartis AG Common Stock | Sell | $1,001 - $15,000 | 363d ago | — | |
| 2025-07-22 | NVSNovartis AG Common Stock | Sell | $1,001 - $15,000 | 433d ago | — | |
| 2025-06-11 | NVSNovartis AG Common Stock | Buy | $1,001 - $15,000 | 433d ago | — | |
| 2025-03-24 | NVSNovartis AG Common Stock | Sell | $100,001 - $250,000 | 545d ago | — | |
| 2023-07-10 | NVSNovartis AG Common Stock | Sell | $50,001 - $100,000 | 1164d ago | — | |
| 2023-03-31 | NVSNovartis AG Common Stock | Buy | $50,001 - $100,000 | 1282d ago | — |
2026-08-27
Kevin Hern
NVS
Amount
$15,001 - $50,000
Filed
25d ago
2025-10-30
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
333d ago
2025-09-25
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
363d ago
2025-07-22
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
433d ago
2025-06-11
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
433d ago
2025-03-24
George Whitesides
NVS
Amount
$100,001 - $250,000
Filed
545d ago
2023-07-10
Daniel Goldman
NVS
Amount
$50,001 - $100,000
Filed
1164d ago
2023-03-31
Daniel Goldman
NVS
Amount
$50,001 - $100,000
Filed
1282d ago
Recent News
Powered by Polygon.io
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer
Cancer Stocks to Consider as Oncology Innovation Accelerates
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Trade Timeline
Congressional activity, newest first
Kevin Hern
2026-08-27 · Sale
$15,001 - $50,000
Lisa McClain
2025-10-30 · Purchase
$1,001 - $15,000
Lisa McClain
2025-09-25 · Sale
$1,001 - $15,000
Lisa McClain
2025-07-22 · Sale
$1,001 - $15,000
Lisa McClain
2025-06-11 · Purchase
$1,001 - $15,000
George Whitesides
2025-03-24 · Sale
$100,001 - $250,000
Daniel Goldman
2023-07-10 · Sale
$50,001 - $100,000
Daniel Goldman
2023-03-31 · Purchase
$50,001 - $100,000